Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

How Fast Is The Chronic Plaque Psoriasis Market Expected to Grow Between 2025 And 2029?

The market size for chronic plaque psoriasis has seen significant growth in the past few years. The projection suggests an increase from $20.79 billion in 2024 to $22.32 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 7.3%. The upward trend during the historic phase can be linked to factors such as an increased number of psoriasis cases, higher rates of co-morbidities, beneficial reimbursement policies, a surge in alcohol and tobacco use, and the emergence of telemedicine.

In the upcoming years, the market size for chronic plaque psoriasis is projected to experience robust growth, eventually reaching $29.33 billion at a compound annual growth rate (CAGR) of 7.1% by 2029. This growth during the projected period is attributable to various factors such as an increase or decrease in global cpp prevalence, the surge in autoimmune diseases, augmentation in healthcare budgets, the aging population, and a rising demand for effective treatments. Noticeable trends during this period involve advancements in biologic treatments, the emergence of oral small molecule inhibitors, the integration of digital health, personalized medicine, and the introduction of biosimilars.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Chronic Plaque Psoriasis Market?

The rise in immune system dysfunction cases is projected to fuel the expansion of the chronic plaque psoriasis market. This condition occurs when the immune system does not perform efficiently, resulting in a heightened risk of infections, autoimmune diseases, and cancer. A multitude of factors such as genetic predispositions, environmental factors, malnutrition, chronic stress, and the increasing occurrence of autoimmune diseases and infections like HIV are believed to contribute to this increase in immune system dysfunction. Treatment for chronic plaque psoriasis is crucial in managing this dysfunction, as the immune system erroneously stimulates an overproduction of skin cells, causing inflammation and plaque formation. For instance, in December 2022, the National Psoriasis Foundation, a nonprofit organization based in the US, stated that over 8 million Americans battle with psoriasis. This condition affects 125 million people worldwide, which represents 2 to 3% of the global population. Consequently, the escalating cases of immune system dysfunction are spurring the chronic plaque psoriasis market’s growth.

Which Key Market Segments Comprise the Chronic Plaque Psoriasis Market and Drive Its Revenue Growth?

The chronic plaque psoriasis market covered in this report is segmented –

1) By Drug Class: Biologics, Small Molecule Drugs

2) By Route Of Administration: Injectable, Oral, Topical

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors, Others

2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids, Others

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

Which Areas Are Leading Regions in the Chronic Plaque Psoriasis Market Expansion Across the Globe?

North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in the Chronic Plaque Psoriasis Market Over the Coming Years?

The chief businesses active in the chronic plaque psoriasis market are channeling their efforts into creating novel treatments, such as IL-17A and IL-17F inhibitors. These innovations aim to improve the treatment process of chronic plaque psoriasis. IL-17A and IL-17F inhibitors are specialized biological treatments that obstruct interleukin-17A and interleukin-17F. These inflammation-causing cytokines contribute to the immune response, and their inhibition results in decreases inflammation in autoimmune disorders like chronic plaque psoriasis. As an illustration, in October 2023, UCB S.A., a biopharmaceutical firm based in Belgium, announced that the US Food and Drug Administration (FDA) had approved BIMZELX (bimekizumab-bkzx) for use in adults diagnosed with moderate to severe plaque psoriasis who qualify for systemic therapy or phototherapy. Bimekizumab, which specifically targets and blocks interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two crucial inflammation-causing cytokines, was the first medication approved for psoriasis. The drug’s approval was based on evidence derived from three multicenter Phase 3 trials—BE READY, BE VIVID, and BE SURE—which collectively examined its safety and effectiveness in treating 1,480 patients with moderate to severe plaque psoriasis.

View the full report here:

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

How Is the Chronic Plaque Psoriasis Market Conceptually Defined?

Chronic plaque psoriasis is a persistent, inflammatory skin condition characterized by the formation of well-defined, raised, red patches covered with silvery-white scales. These plaques most commonly appear on the scalp, elbows, knees, and lower back but can occur anywhere on the body. It is an autoimmune disorder in which the immune system triggers an accelerated turnover of skin cells, leading to their buildup on the surface.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20726

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model